-+ 0.00%
-+ 0.00%
-+ 0.00%

Ascendiant Capital Maintains Buy on ENDRA Life Sciences, Lowers Price Target to $50

Benzinga·04/21/2025 10:41:15
Listen to the news
Ascendiant Capital analyst Edward Woo maintains ENDRA Life Sciences (NASDAQ:NDRA) with a Buy and lowers the price target from $75 to $50.